JSF Financial’s Regeneron Pharmaceuticals REGN Stock Holding History

JSF Financial’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-828	Closed	-$870K	–	134
2024 Q3	$870K	Buy	828 +68	+9%	+$75.7K	0.25%	59
2024 Q2	$799K	Buy	760 +49	+7%	+$47.5K	0.24%	56
2024 Q1	$684K	Buy	711 +53	+8%	+$50.4K	0.21%	64
2023 Q4	$578K	Buy	658 +4	+0.6%	+$3.29K	0.2%	60
2023 Q3	$538K	Buy	+654	New	+$514K	0.21%	60
2023 Q2	–	Sell	-761	Closed	-$625K	–	118
2023 Q1	$625K	Buy	761 +59	+8%	+$44.5K	0.23%	58
2022 Q4	$506K	Buy	702 +17	+2%	+$12.5K	0.19%	76
2022 Q3	$472K	Buy	+685	New	+$431K	0.18%	74
2022 Q2	–	Sell	-296	Closed	-$207K	–	118
2022 Q1	$207K	Buy	+296	New	+$187K	0.09%	108
2020 Q4	–	Sell	-365	Closed	-$204K	–	95
2020 Q3	$204K	Buy	+365	New	+$221K	0.16%	72

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JSF Financial's REGN Position: Q4 2024 in Review

JSF Financial sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 828 shares — an estimated $870K sold.

JSF Financial first reported a position in REGN in Q3 2020 and held it in 10 quarters. The position peaked at $870K in Q3 2024. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

JSF Financial reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
JSF Financial sold 828 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $870K.
JSF Financial first reported a position in Regeneron Pharmaceuticals in Q3 2020 and held it in 10 quarters.
JSF Financial's Regeneron Pharmaceuticals position peaked at $870K in Q3 2024.
1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on JSF Financial's 13F filing for Q4 2024, filed 29 Jan 2025.